Zymeworks Inc. is a publicly listed (TSX/NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development – plus...engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates.
Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in a Phase 2 clinical trial. Zymeworks’ second candidate, ZW49, is a bispecific antibody-drug conjugate (ADC), which has entered into a Phase 1 clinical trial.
Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies. – moins